52 results about "Renal inflammation" patented technology

A remedy and / or a preventive for a chronic disease which contains an EDG-2 antagonist. Because of binding to a subtype EDG-2 of LPA receptor, an EDG-2 antagonist is useful in treating and / or preventing chronic diseases (for example, diseases caused by the progress of chronic asthma, glomerular nephritis, obesity, arteriosclerosis, rheumatoid and atopic diseases) induced and made chronic by tissue cells whose proliferation is accelerated by LPA mediated by EDG-2.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I)(wherein, all the symbols have the same meanings as that of the specification) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.

The invention relates to a lactobacillus acidophilus KBL409 strain and an application of the lactobacillus acidophilus KBL409 strain. The Lactobacillus acidophilus KBL409 strain (registration number KCTC 13518BP) according to the present invention alleviates renal inflammation and the concentration of uremic substances (such as blood urea nitrogen, creatinine, p-cresol and the like) in blood to protect the kidney, and exhibits the effects of proteinuria alleviation, renal mitochondrial function recovery and renal fibrosis inhibition. And therefore, the compound can be effectively applied to improvement of renal function and prevention and treatment of nephropathy (including chronic nephropathy).

The invention belongs to the technical field of medicine and particularly relates to an application of a traditional Chinese medicine composition in preparation of medicine for treating kidney disease. The traditional Chinese medicine composition is obtained by performing ethanol extracting on the following raw materials: 6-10 parts of giant knot weed, 5-8 parts of plantain herb, 5-8 parts of glossy privet fruit and 1-4 parts of beehive. The traditional Chinese medicine composition can be used for treating the kidney diseases such as diabetic nephropathy, renal edema and renal edema, and is quick in effect, short in course of treatment, high in cure rate and low in toxic side effect, and also is simple in operation process, stable in medical effect and easy to popularize.

Provided are compounds of Formula (I):The compounds target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.

Disclosed are antagonists of PC3-secreted microprotein (PSMP) and use of the antagonists for treatment of liver, lung, or kidney fibrosis, including various diseases or disorders associated with liver, lung, or kidney fibrosis such as, e.g., non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), drug-induced lung injury, acute kidney injury (AKI), chronic kidney disease (CKD), lupus nephritis, IgA nephropathy, and membranous glomerulonephritis. Also disclosed are PSMP antagonists and their use for treatment of graft-versus-host disease (GVHD) and systemic lupus erythematosus (SLE). Suitable PSMP antagonists for use in disease treatment include PSMP-binding proteins such as, for example, neutralizing anti-PSMP antibodies.

The invention discloses the use of a class of methyl salicylate glycoside compounds represented by the general formula (1) and pharmaceutically acceptable salts thereof in the preparation of medicines for preventing and / or treating systemic lupus erythematosus and its complications. In the present invention, methyl salicylate glycoside has the pharmacological effect of reducing the expression levels of autoantibodies and inflammatory factors in lupus mice and improving immune function; it has the effect of slowing down the pathological process of lupus arthritis; The pharmacological effect of immune complex deposition and improving renal function in lupus mice; it has the effect of protecting spleen function in lupus mice. Methyl salicylate glycosides are monomeric compounds extracted and separated from the traditional Chinese herbal medicine Dianbaizhu, which has the advantages of low toxicity, simple extraction process, and mature synthetic route; its raw material resources are vast, and it is easy to prepare in large quantities. With good application and development prospects, it is an ideal new type of traditional Chinese medicine monomer for the treatment of complications such as systemic lupus erythematosus and its immune dysfunction, lupus arthritis, lupus nephritis, and lupus spleen injury.